Browse the evidence

Obesity and overweight status are strongly associated with higher odds of dyslipidemia in Iranian adults, with obese individuals having 2.8 times higher risk compared to normal-weight adults.

Maintaining a healthy weight is crucial for managing blood lipids. In this population, obesity significantly increases the risk of dyslipidemia. Focus on sustainable lifestyle changes including balanced nutrition and regular physical activity to manage weight and improve lipid profiles.

Physical inactivity is associated with increased odds of dyslipidemia, with inappropriate physical activity increasing the odds by 1.2 times compared to appropriate activity.

Regular physical activity helps manage blood lipids. This study found that those with inappropriate physical activity had higher odds of dyslipidemia. Aim for regular moderate-to-vigorous physical activity as part of a healthy lifestyle.

Low-carbohydrate weight-reducing diets produce greater short-term weight loss (3-12 months) than balanced-carbohydrate diets in overweight/obese adults without type 2 diabetes, but this advantage disappears after 12 months.

If you want to lose weight quickly, a low-carb diet might give you a slight edge over a balanced diet in the first year. However, after a year, it offers no advantage over a balanced diet. Choose the diet you can stick to, as long-term weight loss is similar regardless of carb intake.

Sustained weight loss (≥7% at 1 year) is associated with significantly lower HbA1c levels at 10 years compared to weight regain, although A1c may still rise slightly from baseline.

If you lose weight through lifestyle changes, keeping it off is crucial for long-term blood sugar control. Even if your blood sugar rises slightly from its lowest point, keeping 7% or more weight off keeps it significantly lower than if you regain the weight. This helps protect your kidneys over the next decade.

Long-term use of GLP-1 receptor agonists (GLP-1RAs) reduces the incidence of knee surgery and slows cartilage loss velocity in knee osteoarthritis (KOA) patients with comorbid type 2 diabetes, primarily mediated by significant weight loss rather than direct anti-inflammatory effects.

If you have knee osteoarthritis and type 2 diabetes, using GLP-1RAs (like semaglutide or liraglutide) for at least two years can significantly reduce your risk of needing knee surgery and slow down cartilage wear. This benefit comes mainly from the weight loss these drugs cause, which reduces stress on your knees. While they also help with pain, the structural protection is largely weight-dependent. To maximize benefits, combine GLP-1RA therapy with resistance training to preserve muscle mass.

Dietary composition, particularly high carbohydrate intake, can reduce post-weight-loss metabolic expenditure by approximately 200 kcal/day compared to higher fat intakes, contributing to weight regain.

After weight loss, be mindful of high-carbohydrate diets, especially if you have insulin resistance. Higher fat or lower carbohydrate intakes may help preserve metabolic rate, making it easier to maintain your weight.

Lifestyle interventions (diet and physical activity) alone result in modest weight loss (2-9%) and are often insufficient for significant health improvements, though they remain a fundamental component of obesity management.

Lifestyle changes are essential but often result in only modest weight loss (2-9%) that is hard to maintain. For significant health improvements, lifestyle changes should be combined with other treatments like medications or surgery, especially if you have obesity-related health conditions.

SGLT-2 inhibitors and DPP-4 inhibitors produce modest or neutral weight loss effects, respectively, making them less effective for weight management compared to GLP-1 agonists.

SGLT-2 inhibitors offer modest weight loss (3-5%), while DPP-4 inhibitors are generally weight-neutral or have mild effects. They are less effective for weight management than GLP-1 agonists. SGLT-2 inhibitors work by excreting glucose in urine, but compensatory mechanisms limit weight loss. DPP-4 inhibitors are better suited for glycemic control without significant weight impact.

Weight loss outcomes (kg or % loss) in behavioral interventions do not consistently favor either 'more' or 'less' advantaged groups, with most trials finding no significant difference in weight loss by socioeconomic or demographic status.

Your socioeconomic background does not predict your weight loss success. While you might face more barriers to starting or sticking with a program, if you do complete it, you are likely to lose the same amount of weight as anyone else.

Weight cycling (yo-yo dieting) is associated with increased cardiovascular risk and morbidity, whereas sustained weight loss or maintenance reduces risk.

Avoid yo-yo dieting. Repeatedly losing and regaining weight increases your risk of heart disease. Focus on sustainable weight loss or maintenance. If you struggle with weight cycling, seek professional help to establish stable habits.

Greater degrees of weight reduction achieved with tirzepatide are associated with greater improvements in health-related quality of life (HRQoL), particularly when weight loss is ≥5%.

With tirzepatide, you don't need to lose a massive amount of weight to see benefits. Losing 5% or more of your body weight is associated with noticeable improvements in how you feel and function, with greater losses leading to even better outcomes.

Sustained lockdown-induced sedentary behavior and dietary shifts in healthy adults cause significant worsening of cardiovascular risk factors, including increased BMI, body fat, LDL cholesterol, blood glucose, and blood pressure.

Maintain physical activity and monitor dietary intake during periods of restricted movement. The study shows that even healthy adults experience measurable declines in metabolic health (weight, lipids, glucose) when sedentary, highlighting the need for proactive lifestyle management during lockdowns or similar restrictions.

Very low-calorie diets (VLCD) are suitable for short-term use in specific clinical populations, such as those with Type 2 Diabetes (T2D), to improve glycemic control and cardiovascular risk factors, but are not recommended for long-term use or for older adults at risk of sarcopenia.

If you have Type 2 Diabetes, a very low-calorie diet might help your blood sugar and weight quickly, but only under doctor supervision and for a short time. Do not use this if you are older and worried about muscle loss.

Physical activity improves metabolic health and reduces blood glucose levels independently of weight loss and insulin signaling pathways.

You do not need to lose weight to get the metabolic benefits of exercise. Even if your weight stays the same, physical activity helps your muscles take up glucose without relying on insulin, which is crucial for preventing or managing type 2 diabetes and metabolic syndrome. Focus on consistency rather than just the number on the scale.

Humans exhibit sensitivity to meal energy density (ED) by adjusting meal size to minimize acute aversive effects of overconsumption, specifically through a nonlinear relationship where calorie-content signals dominate at high EDs (>1.41-1.75 kcal/g).

Your body naturally regulates intake based on how energy-dense your food is. When you eat foods with high energy density (above ~1.5 kcal/g), your body uses calorie-sensing signals to reduce your meal size, preventing overconsumption. This is a learned and biological response, not just stomach volume. Focus on understanding that high-energy foods trigger different satiety signals than low-energy, high-volume foods.

Anti-obesity medications and bariatric surgery improve Obstructive Sleep Apnea (OSA) severity, measured by Apnea-Hypopnea Index (AHI), in direct proportion to the percentage of body weight lost, regardless of the specific intervention type.

If you have OSA and are overweight, losing weight through medication or surgery will improve your sleep apnea severity. For every 1% of body weight you lose, your Apnea-Hypopnea Index (AHI) drops by about 0.45 events per hour. This benefit is consistent whether you lose the weight through medication or surgery, meaning you can choose the method that fits your lifestyle and risk tolerance while expecting similar proportional improvements in your sleep apnea.

Low-carbohydrate diets lead to significant short-term reductions in body weight, BMI, and waist circumference in overweight/obese T2DM patients, but these advantages may attenuate over the long term (6-24 months) compared to balanced low-calorie diets.

You can expect to lose weight, BMI, and waist circumference quickly in the first few months on a low-carb diet. However, do not be discouraged if your weight loss slows down after 6 months; studies show that over the long term, your results will likely be similar to those of any balanced, calorie-controlled diet. The key is sustainability and adherence rather than expecting indefinite rapid loss.

Intensive lifestyle intervention in patients with Type 2 Diabetes and obesity does not significantly reduce major cardiovascular events compared to standard care, although weight loss of 10% or more is associated with a lower risk.

For Type 2 Diabetes patients, intensive lifestyle changes alone may not significantly reduce heart events compared to standard care, unless you achieve at least 10% weight loss. Focus on sustainable weight loss and combine lifestyle changes with medical therapies for best heart protection.

Intermittent fasting variants (ADF, TWF, TRE) produce weight and fat loss effects equivalent to daily caloric restriction (DCR) when total energy intake is matched, with no inherent metabolic advantage to fasting timing.

Use intermittent fasting if it helps you eat less, not because you think it burns fat faster. If you can maintain a caloric deficit with standard meal timing, you will lose fat at the same rate. Prioritize protein intake and resistance training to protect muscle, as fasting does not inherently spare muscle.

Despite significant losses in absolute muscle strength and lean mass, relative muscle strength (strength per unit of body weight or lean mass) and physical function (sit-to-stand time, 6-minute walk distance) improve significantly within one year of metabolic/bariatric surgery, regardless of the specific surgical procedure.

You will lose some muscle mass and absolute strength after surgery, which is normal. However, because you are losing a lot of body weight, your relative strength (strength for your body size) and physical function (walking, standing up) will likely improve. Focus on maintaining muscle through protein intake and light activity rather than fearing the inevitable loss.

Lifestyle interventions for type 2 diabetes prevention in women with a history of gestational diabetes are only effective in reducing T2DM risk if participants have a baseline mean BMI of 30 kg/m2 or higher.

If you have a history of gestational diabetes and a BMI of 30 or higher, lifestyle interventions (diet and exercise) are highly effective at preventing type 2 diabetes. If your BMI is lower, these interventions may not significantly reduce your T2DM risk, though they may still help with weight management.

Metabolic bariatric surgery (specifically malabsorptive procedures like Roux-en-Y gastric bypass) offers higher remission rates for Type 2 Diabetes than restrictive procedures (like sleeve gastrectomy), particularly in patients with severe obesity (BMI ≥ 35).

If you have severe obesity (BMI 35+) and Type 2 Diabetes, metabolic surgery (specifically bypass) is the most effective intervention for remission, offering double the success rate of sleeve gastrectomy. While invasive, it provides superior long-term glycemic control and lower relapse rates compared to other surgical options.

Physical activity levels are significantly lower in obese patients with Type 2 Diabetes compared to non-obese patients, and this difference persists even when total energy intake is similar between groups.

Obese diabetic patients tend to be significantly less physically active than non-obese patients. Since calorie intake may not differ, increasing physical activity is a critical component of weight management.

Waist circumference (WC) is a critical, 'vital' parameter for assessing cardiovascular risk in obesity, providing prognostic information that BMI alone fails to capture, particularly regarding visceral adipose tissue (VAT).

Ask your doctor to measure your waist circumference at every visit. It is a key indicator of heart disease risk that weight alone cannot show, especially if you have a 'normal' weight but carry fat around your midsection.